China Resources Pharmaceutical Group Limited

SEHK:3320 Rapport sur les actions

Capitalisation boursière : HK$34.8b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

China Resources Pharmaceutical Group Gestion

Gestion contrôle des critères 3/4

Le PDG China Resources Pharmaceutical Group's est Xiaosong Bai, nommé en Jan2022, a un mandat de 2.58 ans. La rémunération annuelle totale est CN¥ 3.60M, composée du salaire de 98.6% et des bonus 1.4%, y compris les actions et options de la société. détient directement 0.003% des actions de la société, d'une valeur de HK$ 1.13M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.6 ans et 3.9 ans.

Informations clés

Xiaosong Bai

Directeur général

CN¥3.6m

Rémunération totale

Pourcentage du salaire du PDG98.6%
Durée du mandat du directeur général2.6yrs
Propriété du PDG0.003%
Durée moyenne d'occupation des postes de direction2.6yrs
Durée moyenne du mandat des membres du conseil d'administration3.9yrs

Mises à jour récentes de la gestion

Recent updates

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17
Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued

Feb 14
An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued

If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%

Jan 17
If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Nov 29
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Analyse de la rémunération des PDG

Comment la rémunération de Xiaosong Bai a-t-elle évolué par rapport aux bénéfices de China Resources Pharmaceutical Group?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2023CN¥4mCN¥4m

CN¥4b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥2mCN¥2m

CN¥4b

Rémunération vs marché: La rémunération totale de Xiaosong ($USD 504.53K ) est dans la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 505.05K ).

Rémunération et revenus: La rémunération de Xiaosong a augmenté de plus de 20 % au cours de l'année écoulée.


PDG

Xiaosong Bai (53 yo)

2.6yrs

Titularisation

CN¥3,601,000

Compensation

Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Xiaosong Bai
CEO & Executive Director2.6yrsCN¥3.60m0.0032%
CN¥ 1.1m
Ran Tao
VP & Executive Director2.9yrsCN¥2.94mpas de données
Rong Deng
CFO & Executive Director1.2yrspas de donnéespas de données
Lu Ge
Chief Information Officer & VP10.7yrspas de donnéespas de données
Kwai Cheng
Company Secretaryless than a yearpas de donnéespas de données
Jianjun Wu
Vice Presidentno datapas de donnéespas de données
Kai Qiu
Vice President of CR Pharma & Chairman of China Resources Boyano datapas de donnéespas de données

2.6yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 3320 est considérée comme expérimentée (ancienneté moyenne 2.6 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Xiaosong Bai
CEO & Executive Director2.6yrsCN¥3.60m0.0032%
CN¥ 1.1m
Ran Tao
VP & Executive Director2.9yrsCN¥2.94mpas de données
Rong Deng
CFO & Executive Directorless than a yearpas de donnéespas de données
Tingmei Fu
Independent Non-Executive Director8.2yrsCN¥270.00kpas de données
Ruifang Jiao
Non-Executive Director2.6yrspas de donnéespas de données
Kejian Zhang
Independent Non-Executive Director8.2yrsCN¥270.00kpas de données
Kin Fun Kwok
Independent Non-Executive Director8.2yrsCN¥270.00kpas de données
Yi Feng
Chairman of China Resources Double-Crane Pharmaceutical Co.5.7yrspas de donnéespas de données
Wei Guo
Non-Executive Director1.5yrspas de donnéespas de données
Mo Han Shing
Independent Non-Executive Director7yrsCN¥270.00kpas de données
Yuewei Han
Chairman4.8yrspas de données0.0048%
CN¥ 1.7m
Yongqiang Sun
Non-Executive Directorless than a yearpas de donnéespas de données

3.9yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 3320 sont considérés comme expérimentés (ancienneté moyenne 3.9 ans).